CN104619714A - 异噁唑烷衍生物 - Google Patents

异噁唑烷衍生物 Download PDF

Info

Publication number
CN104619714A
CN104619714A CN201380047423.2A CN201380047423A CN104619714A CN 104619714 A CN104619714 A CN 104619714A CN 201380047423 A CN201380047423 A CN 201380047423A CN 104619714 A CN104619714 A CN 104619714A
Authority
CN
China
Prior art keywords
oxo
phenyl
chloro
dimethyl
phenanthrene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380047423.2A
Other languages
English (en)
Chinese (zh)
Inventor
E·吉蒂尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47044778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104619714(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Priority to CN201810340325.2A priority Critical patent/CN108440637A/zh
Publication of CN104619714A publication Critical patent/CN104619714A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0068—Nitrogen and oxygen at position 16(17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Otolaryngology (AREA)
CN201380047423.2A 2012-09-13 2013-08-23 异噁唑烷衍生物 Pending CN104619714A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810340325.2A CN108440637A (zh) 2012-09-13 2013-08-23 异噁唑烷衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12184286 2012-09-13
EP12184286.8 2012-09-13
PCT/EP2013/067509 WO2014040837A1 (en) 2012-09-13 2013-08-23 Isoxazolidine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810340325.2A Division CN108440637A (zh) 2012-09-13 2013-08-23 异噁唑烷衍生物

Publications (1)

Publication Number Publication Date
CN104619714A true CN104619714A (zh) 2015-05-13

Family

ID=47044778

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810340325.2A Pending CN108440637A (zh) 2012-09-13 2013-08-23 异噁唑烷衍生物
CN201380047423.2A Pending CN104619714A (zh) 2012-09-13 2013-08-23 异噁唑烷衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810340325.2A Pending CN108440637A (zh) 2012-09-13 2013-08-23 异噁唑烷衍生物

Country Status (28)

Country Link
US (2) US9155747B2 (enExample)
EP (1) EP2895495B1 (enExample)
JP (2) JP2015533801A (enExample)
KR (1) KR101719524B1 (enExample)
CN (2) CN108440637A (enExample)
AR (1) AR092547A1 (enExample)
AU (1) AU2013314539B2 (enExample)
BR (1) BR112015005500B1 (enExample)
CA (1) CA2884705C (enExample)
CL (1) CL2015000610A1 (enExample)
EA (1) EA027034B1 (enExample)
ES (1) ES2672140T3 (enExample)
GE (1) GEP201706708B (enExample)
HK (1) HK1209756A1 (enExample)
IL (1) IL237686A (enExample)
MA (1) MA37927B2 (enExample)
MX (1) MX364865B (enExample)
MY (1) MY182523A (enExample)
NZ (1) NZ705902A (enExample)
PE (1) PE20150675A1 (enExample)
PH (1) PH12015500534B1 (enExample)
PL (1) PL2895495T3 (enExample)
SA (1) SA515360134B1 (enExample)
SG (1) SG11201501902RA (enExample)
TN (1) TN2015000093A1 (enExample)
UA (1) UA116545C2 (enExample)
WO (1) WO2014040837A1 (enExample)
ZA (1) ZA201501691B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115785188A (zh) * 2022-12-20 2023-03-14 湖南醇健制药科技有限公司 一种布地奈德的制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193262A1 (en) 2011-03-15 2013-10-30 Chiesi Farma Spa Isoxazolidine derivatives
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (en) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482318A (zh) * 2009-09-11 2012-05-30 奇斯药制品公司 异噁唑烷衍生物
WO2012123482A2 (en) * 2011-03-15 2012-09-20 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
WO2013017374A1 (en) * 2011-08-01 2013-02-07 Chiesi Farmaceutici S.P.A. Anti -inflammatory steroids condensed in position 16,17 with pyrrolidine ring

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31997A (en) * 1968-05-03 1974-03-14 Lepetit Spa Process for the preparation of pregnano(17alpha,16alpha-d)oxazolines and 16alpha,21-dihydroxy-17alpha-aminopregnanes
SE378110B (enExample) * 1972-05-19 1975-08-18 Bofors Ab
JPS617293A (ja) * 1984-06-20 1986-01-13 Mitsubishi Chem Ind Ltd 新規なコルチコイド誘導体およびその製法
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
WO2003070745A2 (en) * 2002-02-20 2003-08-28 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
NO331891B1 (no) * 2007-03-20 2012-04-30 Clavis Pharma Asa Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
MX2010009022A (es) * 2008-02-27 2010-09-07 Astrazeneca Ab Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
TW201139369A (en) 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
BR112013022890A2 (pt) 2011-03-15 2016-09-13 Chiesi Farma Spa composto, composição farmacêutica, combinação e uso de um composto

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482318A (zh) * 2009-09-11 2012-05-30 奇斯药制品公司 异噁唑烷衍生物
WO2012123482A2 (en) * 2011-03-15 2012-09-20 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
WO2013017374A1 (en) * 2011-08-01 2013-02-07 Chiesi Farmaceutici S.P.A. Anti -inflammatory steroids condensed in position 16,17 with pyrrolidine ring

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115785188A (zh) * 2022-12-20 2023-03-14 湖南醇健制药科技有限公司 一种布地奈德的制备方法
CN115785188B (zh) * 2022-12-20 2024-06-07 湖南科益新生物医药有限公司 一种布地奈德的制备方法

Also Published As

Publication number Publication date
US9155747B2 (en) 2015-10-13
EA201590390A1 (ru) 2015-08-31
HK1209756A1 (en) 2016-04-08
MA37927B2 (fr) 2021-08-31
GEP201706708B (en) 2017-07-25
BR112015005500A2 (pt) 2018-05-22
CA2884705C (en) 2021-04-13
AU2013314539B2 (en) 2018-03-08
MY182523A (en) 2021-01-25
MX2015002898A (es) 2015-06-03
PL2895495T3 (pl) 2018-10-31
KR20150042264A (ko) 2015-04-20
JP2015533801A (ja) 2015-11-26
UA116545C2 (uk) 2018-04-10
WO2014040837A1 (en) 2014-03-20
BR112015005500B1 (pt) 2022-11-22
ES2672140T3 (es) 2018-06-12
US9469669B2 (en) 2016-10-18
JP6736607B2 (ja) 2020-08-05
MX364865B (es) 2019-05-09
PH12015500534A1 (en) 2015-05-04
CL2015000610A1 (es) 2015-12-04
PE20150675A1 (es) 2015-05-20
PH12015500534B1 (en) 2019-01-23
EP2895495B1 (en) 2018-05-16
AU2013314539A1 (en) 2015-04-02
SA515360134B1 (ar) 2016-07-24
NZ705902A (en) 2018-04-27
MA20150350A1 (fr) 2015-10-30
CA2884705A1 (en) 2014-03-20
EP2895495A1 (en) 2015-07-22
CN108440637A (zh) 2018-08-24
SG11201501902RA (en) 2015-04-29
US20140069419A1 (en) 2014-03-13
ZA201501691B (en) 2016-10-26
JP2018162270A (ja) 2018-10-18
IL237686A (en) 2017-10-31
KR101719524B1 (ko) 2017-03-24
AR092547A1 (es) 2015-04-22
TN2015000093A1 (en) 2016-06-29
US20150376226A1 (en) 2015-12-31
EA027034B1 (ru) 2017-06-30

Similar Documents

Publication Publication Date Title
TWI494318B (zh) 異唑啶衍生物
JP6736607B2 (ja) イソキサゾリジン誘導体
US10280193B2 (en) Isoxazolidine derivatives
US8835412B2 (en) Isoxazolidine derivatives
HK1259584A1 (en) Isoxazolidine derivatives
HK1189599A (en) Isoxazolidine derivatives
HK1190723B (en) Isoxazolidine derivatives
HK1196969A (en) Anti-inflammatory steroids condensed in position 16, 17 with pyrrolidine ring

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1209756

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150513

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1209756

Country of ref document: HK